TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06732648: The Efficacy and Safety of Intravenous HRS8179 for the Prevention and Treatment of Severe Cerebral Edema Following Large Hemispheric Infarction: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II/III C

Sponsor: Beijing Suncadia Pharmaceuticals Co., Ltd · Phase: PHASE2/PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 725 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,961,280

Rescue Site Savings

+$8,546,344

Unlock Full NCT06732648 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06732648 Rescue Dossier →